Management of obesity: Medical treatment options

American Family Physician

Volumn 55, Issue 2, 1997, Pages 551-558

  Carek, Peter J ^a   Sherer, Jeffrey T ^a   Carson, Deborah Stier ^a   Pharm, D ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DIABETES MELLITUS; DIETARY INTAKE; EXERCISE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; OBESITY; RISK FACTOR; WEIGHT REDUCTION;

AMPHETAMINES; APPETITE DEPRESSANTS; DIABETES MELLITUS; DRUGS, INVESTIGATIONAL; ENERGY METABOLISM; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; OBESITY; RISK; SEROTONIN AGENTS; UNITED STATES; WEIGHT LOSS;

EID: 0031019765     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Gray DS. Diagnosis and prevalence of obesity. Med Clin North Am 1989;73:1-13.
2. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among U.S. adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA 1994;272:205-11.
3. Testimony of Janet D. Steiger, chairman, Federal Trade Commission. Hearing Before the Subcommittee on Regulation, Business Opportunities and Energy of the House Committee on Small Business, March 26, 1990.
4. Levy AS, Heaton AW. Weight control practices of U.S. adults trying to lose weight. Ann Intern Med 1993;119(7 Pt 2):661-6.
5. Serdula MK, Collins ME, Williamson DF, Anda RF, Pamuk E, Byers TE, et al. Weight control practices of U.S. adolescents and adults. Ann Intern Med 1993;119(7 Pt 2):667-71.
6. Bray GA. Obesity: definition, diagnosis and disadvantages. Med J Australia 1985;142(7 Suppl):2-8.
7. Van Itallie TB. Health implications of overweight and obesity in the United States. Ann Intern Med 1985;103(6 Pt 2):983-8.
8. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med 1993;119(7 Pt 2):655-60.
9. Bray GA. Pathophysiology of obesity. Am J Clin Nutr 1992;55(2 Suppl):488-94.
10. United States National Commission on Diabetes. Report of the National Commission on Diabetes to the Congress of the United States. Bethesda, Md.: National Institutes of Health, 1975; DHEW publication no. 76-1021.
11. Garfinkel L. Overweight and cancer. Ann Intern Med 1985;103(6 Pt 2):1034-6.
12. Colditz GA. Economic costs of obesity. Am J Clin Nutr 1992;55(2 Suppl):503-7.
13. 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. New Engl J Med 1995;333:352-4.
14. 3-adrenergic receptor: a cause and cure of obesity [Editorial]. New Engl J Med 1995;333:382-3.
15. Bray GA. Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann Intern Med 1993;119(7 Pt 2):707-13.
16. NIH consensus statement covers treatment of obesity. Am Fam Physician 1991;44:305-6.
17. Stunkard AJ, Craighead LW, O'Brien R. Controlled trial of behaviour therapy, pharmacotherapy, and their combination in the treatment of obesity. Lancet 1980;2(8203):1045-7.
18. Gordon NF, Scott CB. The role of exercise in the primary and secondary prevention of coronary artery disease. Clin Sports Med 1991;10:87-103.
19. Wellman PJ. Overview of adrenergic anorectic agents. Am J Clin Nutr 1992;55(1 Suppl):193-8.
20. Silverstone T. Appetite suppressants. A review. Drugs 1992;43:820-36.
21. Björntorp P. Regional patterns of fat distribution. Ann Intern Med 1985;103(6 Pt 2):994-5.
22. Jung RT, Chong P. The management of obesity. Clin Endocrinol 1991;35:11-20.
23. Garattini S, Mennini T, Samanin R. Reduction of food intake by manipulation of central serotonin. Current experimental results. Br J Psychiatry 1989;155(Suppl):41-51.
24. Weintraub M, Sundaresan PR, Schuster B. Long-term weight control study. I-VII. Clin Pharmacol Ther 1992;51:581-646.
25. Guy-Grand B, Apfelbaum M, Crepaldi G, Gries A, Lefebvre P, Turner P. International trial of long-term dexfenfluramine in obesity. Lancet 1989;2(8672):1142-5.
26. Bross R, Hoffer LJ. Fluoxetine increases resting energy expenditure and basal body temperature in humans. Am J Clin Nutr 1995;61:1020-5.
27. Goldstein DJ, Rampey AH Jr, Enas GG, Potvin JH, Fludzinski LA, Levine LR. Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obes 1994;18:129-35.
28. Gray DS, Fujioka K, Devine W, Bray GA. Fluoxetine treatment of the obese diabetic. Int J Obes 1992;16:193-8 [Published erratum appears in Int J Obes 1992;16:717].
29. 3-adrenergic agonists. Drugs Future 1993;18:529-49.
30. Yang YT, McElligott MA. Multiple actions of beta-adrenergic agonists on skeletal muscle and adipose tissue. Biochem J 1989;261:1-10.
31. Amgen obesity gene weighs in favorably in July, stock gains 4-3/4 points. FDC Rep Pink Sheet 1995;Aug 7:13-4.